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IGABT was based on MRI in 82% of the patients. Sixty percent were 
treated with high dose rate and the remaining 40% had pulsed dose 
rate BT. Eighty-four percent of the patients were treated with 
intracavitary (IC) technique. In the remaining 16% a combined IC and 
interstitial applicator was used.  
Results: Total prescribed mean dose for HR-CTV (D90) was 89 ±15 Gy, 
D2cc was 89 ±12 Gy for bladder, 64 ±8 Gy for rectum and 65 ±10 Gy for 
sigmoid. At a median follow-up of 31 (3-150) months, two patients had 
died due to morbidity (one fistula and one vaginal bleeding). No other 
G5 events were diagnosed. Actuarial morbidity G3-G5 at 5-years was 
4% for UG tract, 6% for GI tract and 4% for VG. Actuarial morbidity G2-
G5 at 5-years was 19% for UG tract, 18% for GI tract and 22% for VG.  
Conclusions: In this retrospective multicentre study 3D conformal RT 
± cisplatinum and IGABT compares favourble with previous studies on 
morbidity after 2D BT. These findings illustrate that the GEC-ESTRO 
guidelines work in a multicentre setting and serve as benchmark for 
future studies on IGABT for cervical cancer. 
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Purpose/Objective: To give a first interim report on prospectively 
assessed vaginal morbidity in the ongoing EMBRACE study (European 
and International study on MRI-guided brachytherapy in locally ad-
vanced cervical cancer, www.embracestudy.dk) and to describe a 
dose response relationship. Currently, no dose response relationship 
for vaginal morbidity has been established.  
Materials and Methods: Patients with locally advanced cervical 
cancer who underwent combined external beam radiotherapy ± 
chemotherapy and MRI-guided brachytherapy following the GEC-ESTRO 
guidelines were included. Vaginal morbidity was prospectively as-
sessed with CTCAE v.3 at baseline and every 3 months after end of 
treatment for the first 2 years. The assessment included vaginal 
dryness, mucositis, bleeding, stenosis, fistula and any other vaginal 
symptoms (reported in free text field). The dose to the ICRU rectal 
point was used as a surrogate for intermediate to high dose to the 
upper vagina in order to establish a dose effect relationship for vagin-
al morbidity with binary logistic regression analysis (dose response 
curves). 
Results: Information on vaginal morbidity was available in 523 pa-
tients from 19 centers for analysis. Median follow-up was 14 months 
(286 patients with one year and 108 patients with 2 year follow-up). 
Crude incidences of individual vaginal symptoms are shown in table 1; 
no G5 morbidity occurred.  
 Most frequent other vaginal symptoms were adhesions. Actuarial 
analyses resulted in 78% probability of any vaginal morbidity G≥1 and 
19% G≥2 after 1 year, and 92% and 34% after 2 years. In 468 patients, 
information on vaginal morbidity and dose to the ICRU rectal point 
was available. In univariate logistic regression analysis, dose to the 
ICRU rectal point was associated with higher frequency of G≥2 vaginal   
morbidity (p= 0.002, figure 1).   
    
  
 
Conclusions: Severe vaginal morbidity (G3/G4) is rare in the first two 
years after definitive radiochemotherapy including MRI-guided adap-
tive brachytherapy. However, the probability for milder to moderate 
morbidity (G1/G2) is high in the first year (78%) and further increases 
in the second year (92%). The ICRU rectal point dose correlates signif-
icantly with occurrence of G2≥2 vaginal morbidity. Further investiga-
tions with longer follow-up, including the relevance of confounding 
factors, are required. Additionally, analyses of individual vaginal 
endpoints and further dose parameters at the lower and middle 
vagina, especially also sensitive to external beam, are planned and 
will allow in future more detailed conclusions.  
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Purpose/Objective: The purpose of this study was to determine 
feasibility of salvage re-irradiation with high dose rate (HDR) 
brachytherapy and patterns of failures in previously irradiated 
patients diagnosed with recurrent carcinoma of the uterine cervix. 
Materials and Methods: Twenty-eight previously irradiated patients 
presenting with central recurrence with / without early parametrial 
disease and deemed not suitable for exenteration surgery by Gynec 
oncologist, were treated with salvage re-irradiation using HDR 
brachytherapy at our institute. All these patients underwent imaging 
(CT / MR/ PET-CT) to rule out metastatic disease elsewhere in the 
body. Martinez Universal Perineal Interstitial Template (MUPIT) was 
used in 24 patients while Vienna applicator in 4 patients. Median age 
for the cohort was 54 years (range 38-73 years). Median interval 
between two radiation schedules was 25 months (inter-quartile range 
13-49 months). Median delivered dose was 40.3 Gy EQD2 (inter-
quartile range 36.9 - 46.6 Gy). None of the patients received any form 
of Chemotherapy (concomitant / adjuvant /salvage). 
Results: All patients tolerated salvage re-irradiation with HDR 
brachytherapy well. None of the patients reported any significant 
acute toxicity. The median follow up for whole group was 16 months 
(inter-quartile range 7-20 months). Complete response was seen in 21 
patients, partial response in 6 patients and progressive disease in one 
patient on clinic-radiological assessment. At last follow up 15 patients 
were alive, of which 13 were diseases free. Ten patients developed 
central recurrence (biopsy proven), 3 patients had loco-regional 
recurrence while 2 patients had distant metastases. Overall, 
13/28patients developed local recurrence. The local recurrence rate 
was higher inpatients receiving doses less than 40 Gy EQD2.The 
median disease free survival(DFS) and overall survival (OS) was 16 and 
20 months respectively. Two year DFS and OS were 33% and 44% 
respectively. Median DFS was more for patients with more than 25 
month interval between two RT schedules, while tumour size and RT 
dose had no impact on overall DFS. Two patients developed grade III 
radiation proctitis, 3 patients had grade II radiation cystitis and 2 
patients developed grade II bowel complications after re-irradiation. 
One patient required hyperbaric oxygen therapy for chronic non-
healing ulcer at vagina.  
Conclusions: Salvage re-irradiation using HDR brachytherapy is 
feasible in select group of patients with central recurrence. The 
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outcome is comparable with pelvic exenteration surgery and it is 
better with longer interval between two radiation schedules. 
However, larger series and longer follow-up of clinical outcome and 
late toxicities is required for further validation of current promising 
results. 
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Purpose/Objective: The aim of this retrospective study was to 
investigate treatment results and toxicity profile of reirradiation 
treatment in inoperable patients with first local recurrence of cervical 
or vaginal cancer. Additional analysis of clinical and dosimetric 
parameters was undertaken in order to define prognostic factor in this 
cohort. 
Materials and Methods: Between 1997 and 2011, 20 patients have 
been treated at Brachytherapy Department in Warsaw for recurrent 
cervical (19) or vaginal (1) cancer. All patients were deemed 
inoperable or refused surgery. Median age of patients was 62 years 
(range 26-77). Three patients had adenocarcinoma, 16 - squamous cell 
carcinoma and one- carcinoma solidum undifferentiatum. Three 
patients were treated with combined EBRT and brachytherapy. In 9 
patients brachytherapy was associated with hyperthermia treatment. 
The main technique used in brachytherapy applications was 
interstitial (11 patients), followed by vaginal cylinder (6) or 
intraoperative (3). The median EQD2 dose calculated for reirradiation 
treatment was 48,8Gy (range 25-91), and median cumulative EQD2 
dose calculated for primary and reirratiation treatment was 133,5Gy 
(range 96,8-164,2). Early and late toxicity was scored with RTOG and 
RTOG/EORTC scales respectively. Kaplan-Meier estimates for overall 
survival(OS), disease free survival (DFS) and loco-reginal control (LC) 
were calculated. Mantel-Cox’s method was used to define the 
influence of clinical and dosimetric parameters on OS, DFS, LC and 
toxicity profile.  
Results: The 3-year OS (95%CI) was 68% (44%-91%). The 2-year DFS 
(95% CI) was 42.1% (19.4%-64.8%). The 2-year LC (95% CI) was 45.1% 
(21.6%-68.6%). According to Mantel-Cox’s analysis, the time to first 
local failure ≤12 months and tumour diameter > 3cm were both 
adverse prognostic factors affecting OS (p=0.001, 0,001 respectively), 
DFS (p=0.014,0,013 respectively) and LC (p=0.007, 0,005 
respectively). Acute toxicity was acceptable, with no grade 3-4 
radiation related toxic effects reported. GU and GI grade 3 late 
toxicity was observed in 2 patients (10%) and 1 patient (5%) 
respectively.  
Conclusions: Reirradiation with the use of high quality brachytherapy 
is a treatment option in recurrent cervical and vaginal cancers with 
potential for permanent cure. Low level of severe late complications 
encourages total dose escalationin order to increase the chance of 
cure. According to the results of this analysis patients with local 
recurrence diagnosed during the first year of follow up or tumour 
diameter > 3cm should not be treated with radiotherapy again.  
 
 POSTER DISCUSSION: 3: CLINICAL: HEAD& NECK/ 
LUNG  
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Purpose/Objective: Chemoradiotherapy is the standard of care for 
locally advanced head and neck cancer (LAHNC). However, many 
elderly patients are unsuitable for this approach. We report our 
experience of altered fractionated radiotherapy (RT) as a potential 
means of treatment intensification for this population. 
Materials and Methods: A retrospective review was conducted on a 
prospectively assembled cohort of all newly diagnosed LAHNC (stage 
III-IV) in elderly patients (> 70 years old at the diagnosis) treated with 
RT alone in our institution between 1/1/2003 ~ 4/30/2010. RT 
regimens were not randomly assigned and were classified into 3 
categories: a) standard RT (sRT) [70 Gy in 35 fractions over 7 weeks 
(70 Gy/35f/7w)], b) moderated accelerated RT (mRT) over 5 or 6 
weeks (60 Gy/25f/5w, or 70 Gy/35f/6w), and c) very accelerated RT 
(vRT) over 4 weeks (64 Gy/40f/4w, twice daily). Appropriate 
supportive measures were provided during and after RT. Selective use 
of vRT was primarily in patients with good performance status but 
with bulky tumors. Overall survival (OS), locoregional control (LRC), 
distant control (DC), and actuarial late toxicity (>=Grade 3 by 
EORTC/RTOG criteria) were calculated and compared among the sRT, 
mRT and vRT cohorts. Multivariate analysis (MVA) identified predictors 
for OS and LRC. 
Results: A total of 294 patients were included (48 sRT, 178 mRT and 
68 vRT). Disease sites were: oropharynx (113, HPV positive 38, 
negative 32, unascertained 43), larynx (93), oral cavity (33), unknown 
primary (23), hypopharynx (25), and nasal cavity (7). Six patients (2 
sRT and 4 mRT) did not finish the RT and 77 patients (14 sRT, 46 mRT, 
17 vRT) had unplanned breaks during RT. The vRT patients were 
younger (median age: vRT 74.9, sRT 75.2, mRT 76.5 years, p<0.01). 
Smoking pack-years and the proportions of oropharyngeal cancer, T4 
and N2b-N3 category disease were similar among the 3 cohorts. Of the 
183 deaths, 24/35 (69%) sRT, 64/107 (60%) mRT, and 22/41 (53%) vRT 
cases died of their index cancer. 3-year outcomes for the 3 cohorts 
are listed in table 1. MVA revealed mRT was associated with better OS 
(HR 0.62, p=0.02) and LRC (HR 0.49, p<0.01) vs sRT, while vRT was 
also associated with better OS (HR 0.49, p<0.01) and marginally 
improved LRC vs sRT (HR 0.66, p=0.19) when controlling for T- & N-
category, age, smoking pack-years, and disease site. 
 
  
Conclusions: This non-randomized assigned cohort study demonstrates 
an association between altered fractionation RT schedules and 
outcome in elderly patients with LAHNC, without significantly 
increased late toxicity. The benefit of vRT is uncertain, since the 
observations are likely confounded by selection bias (bulkier tumor on 
the one hand and younger fitter patients on the other) and small 
sample size. With appropriate patient selection, altered fractionation 
RT is a valid treatment intensification option for the older population 
in the setting of appropriate supportive management during and 
following RT. 
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Purpose/Objective: To investigate the clinical value of the plasma 
EBV DNA (pEBV DNA) assay in patients with nasopharyngeal carcinoma 
(NPC) after curative treatment. 
